Huberman Lab — Peptides for Repair, Growth Hormone, Longevity & Vitality (solo)

Provenance: educational solo episode — mechanistic + cautionary

A scientist’s solo overview, not clinical practice and not peer-reviewed primary data. Huberman repeatedly stresses that most therapeutic-peptide evidence is animal data with little/no human clinical trial support, and that effects may include placebo. Treat claims as [anecdote] (framework/observation) or [literature-animal] (animal-study mechanism); cautions are [warning]. Research/educational use only. Source: YouTube — zU5EYw06wtw

Key frameworks from this episode

• Peptides are pleiotropic. A single therapeutic peptide activates many pathways across cell types — you cannot isolate one effect, which drives both benefits and side effects. [00:09–00:11]
• Three sourcing tiers: physician-prescribed (FDA-approved / compounding-pharmacy, LPS removed) → gray market (often same peptide, LPS not removed) → black market (often not what the label says). Strong recommendation: prescription + clean source only. [00:02–00:14]
• GH secretagogues split into two categories (Huberman’s relabel for clarity):
  • Type 1 — GHRH-mimetics: Tesamorelin, CJC-1295, and sermorelin (no note yet). Best-tested, several FDA-approved. Cleaner.
  • Type 2 — ghrelin-mimetics (GHRPs): Ipamorelin, hexarelin, GHRP-2/3/6, MK-677 (mostly no notes yet). Also raise ghrelin (hunger/anxiety), and some raise prolactin/cortisol or desensitize receptors.

Claims & cautions by peptide

• BPC-157 — [literature-animal] Promotes angiogenesis at injury sites by recognising injured vessels and upregulating eNOS and VEGF, plus fibroblast migration/growth; modestly upregulates GH receptors. Evidence is overwhelmingly animal (since ~1993); essentially one weak human self-report study — effects could include placebo. [protocol] 300–500 mcg SubQ, 2–3×/week (up to 5); ~8 weeks on, 8–10 weeks off; use minimal effective dose, don’t run continuously. LD50 very high (~2 g/kg) but that is not license to dose high. [warning] Tumor-growth risk — VEGF upregulation is the opposite of the anti-cancer drug Avastin (a VEGF inhibitor); combined with GH-receptor upregulation it can feed/accelerate tumors and neovascular eye disease. Avoid with any cancer/tumor concern. [00:17–00:35, 01:03]
• TB-500 (Thymosin β4) — [literature-animal] Promotes stem-cell proliferation, extracellular-matrix growth, and broad cell-type infiltration for wound repair (vs BPC-157’s vascular focus). Not growth-promoting — does not act on the GH pathway (corrects a common misconception). Often combined with BPC-157. [00:36–00:40, 01:06]
• Tesamorelin (Egrifta) — [anecdote] Type-1 GHRH-mimetic, FDA-approved to reduce visceral adiposity (HIV); longer-lasting than sermorelin → ~3×/week. [00:49–00:51]
• CJC-1295 — [anecdote] Type-1 GHRH-mimetic with a DAC (drug-affinity complex) making it very long-lasting → 1–2×/week. [warning] A death occurred in a clinical trial (cardiovascular dysfunction); known to cause fluid retention/volume increase. Huberman: no clear reason to choose CJC-1295 over sermorelin/tesamorelin until safety is resolved. [00:50–00:52, 00:59] (Contrast: Koniver notes CJC-1295 was later re-allowed for prescription.)
• Ipamorelin — [anecdote] Type-2 (ghrelin-mimetic): raises GH directly and by suppressing somatostatin (releases the brake); raises ghrelin → hunger and some anxiety; deepens sleep (possibly at REM’s expense). [00:54–00:55]
• Epithalon — [literature-animal] Mimics pineal epithalamin; animal data: telomere lengthening, tumor suppression, circadian/melatonin recalibration, anti-inflammatory. Telomere↔longevity link is controversial; no human trials — taking it for lifespan extension is “a leap.” [01:06–01:12]
• PT-141 (Vyleesi) — [anecdote] Melanocortin agonist, FDA-approved for premenopausal hypoactive sexual desire (women), off-label in men. [warning] Side effects: nausea (gut MSH receptors), skin flushing, raised blood pressure, pigmentation; melanoma caution. [01:15–01:17]
• Melanotan II — [anecdote] Crosses the blood-brain barrier (unlike melanotan 1) → raises mood/libido, lowers appetite, plus tanning. Melanoma caution. [01:14–01:15]
• Kisspeptin-10 — [anecdote] Sits upstream of the cascade kisspeptin → GnRH → LH/FSH → testosterone/estrogen; triggers puberty; synthetic form prescribed for hypothalamic amenorrhea; taken for vitality/libido (a “wild card” — recently discovered, pleiotropic). Kisspeptin antagonists treat menopausal vasomotor symptoms. [01:17–01:21]
• HGH — [anecdote] Pituitary growth hormone declines ~15% per decade after 30; exogenous GH triggers negative feedback that suppresses endogenous production (the rationale for using secretagogues instead). [warning] Risks: carpal tunnel, cartilage/bone & facial changes, distended gut, skin-texture changes, and indiscriminate tumor/cancer growth. [00:41–00:45, 01:02–01:04]
• IGF-1 LR3 — [anecdote] GH triggers liver IGF-1 release; IGF-1 is anabolic and regulates blood-sugar metabolism, working synergistically with GH. [00:43–00:44]

New compounds discussed without a note yet (candidates)

sermorelin (type-1, FDA-approved short stature; 200–400 mcg pre-sleep, 3–5×/wk; Huberman: deepens sleep but cut his REM), hexarelin (strongest GH pulse but desensitises GHRH receptors — can shut the system off; raises prolactin), GHRP-2/3/6 (raise GH but also prolactin/cortisol), MK-677 (oral GHRP), melanotan 1/3/4/5, epithalamin (the endogenous peptide epithalon mimics).

Full transcript

Sponsor reads (Mateina, Levels, Juve, AG1, Element) and the closing newsletter/Momentous/social outro have been trimmed ([sponsor segment omitted]); all substantive content preserved with timestamps.

[00:00] Welcome to the Huberman Lab podcast. I’m Andrew Huberman, professor of neurobiology and ophthalmology at Stanford School of Medicine. Today we’re discussing peptides. Peptides are receiving a lot of attention, partly because of excitement about the GLP-1 analogs/agonists (glucagon-like peptides) used for type-2 diabetes and obesity. Today we are not discussing the GLP-1 analogs. We’ll discuss other peptides receiving attention: peptides for tissue healing and repair, and peptides that impact longevity and vitality.

[00:34] Any discussion of peptides could be vast — there are so many. Insulin (blood-glucose regulation) is a peptide. Oxytocin (pair bonding, socialization, milk let-down) is a neuropeptide/hormone. These sit among tens of thousands, perhaps hundreds of thousands, of peptides in the brain and body. Today focuses on peptides increasingly used therapeutically.

[01:29] This is a confusing area — even the naming (BPC-157, MK-677) is confusing. I’ll give a simple organizational framework: what these therapeutic peptides are, why certain ones suit certain purposes, the risks and outright dangers, and how they work alone and in combination toward specific physical and mental-health goals.

[02:25] Applied peptide biology falls into three categories: prescription peptides (FDA-approved, from a physician); gray-market peptides (purchasable online, questionable safety/efficacy); and black-market peptides (do not buy — frequently contaminated, problematic short- and especially long-term).

[03:21] [sponsor segment omitted — Mateina, Levels, Juve]

[07:38] What is a peptide? A small protein made of chains of amino acids. We have many proteins in the body unrelated to dietary protein, though the amino-acid building blocks come from food. Strict definition: chains of ~2–50 amino acids; sometimes up to 75–100 still counts as a peptide. Combine peptides and you get polypeptides; many body proteins are polypeptides. Picture “beads on a string” — 2–100 beads, each an amino acid; their order determines what the peptide is and does.

[09:06] Some peptides are hormones, some are neuromodulators, and most have pleiotropic effects — they affect many aspects of cells. Unlike dopamine or testosterone discussions, a single therapeutic peptide does many different things depending on cell type, time of day, and downstream effects. When a peptide binds a receptor (think “parking spot” on the cell surface), it sets off a bucket-brigade of processes: a growth pathway here, a cell-migration pathway there, a signal to grow blood vessels elsewhere.

[10:31] So with peptide therapeutics we’re rarely talking about a single targeted effect — which matters for expected effects, side effects, dosing, duration, and cycling. Most peptides do anywhere from four to a thousand different things (oxytocin: milk let-down, pair bonding parent-child, etc.). If you want a specific effect — repair an injury, raise growth hormone to get leaner or recover faster — there are peptides for those pathways, but you will always activate other pathways too. The pleiotropy can’t be removed.

[11:52] Three paths to obtain peptides: (1) prescription from a board-certified MD — some are FDA-approved for one use but prescribed off-label (e.g. sermorelin, which promotes GH release, is FDA-approved for short stature but prescribed for other GH-augmentation purposes). The safest, best situation is prescription peptides from a board-certified physician.

[12:48] Why: prescription peptides (from pharma or a compounding pharmacy) are cleaned of lipopolysaccharide (LPS), which accumulates in manufacturing and causes an immune response. A tiny amount may not, but accumulated LPS exposures become problematic. Most peptides are injected subcutaneously or intramuscularly; some oral or topical. Gray-market sources often contain the same peptide but haven’t removed the LPS; black-market sources often aren’t what they claim. I implore you: explore peptides only with a board-certified physician and acquire from a source where LPS is removed (pharma or compounding pharmacy).

[14:43] Four areas we’ll cover: (1) rejuvenation/repair of tissue (muscle, connective tissue, gut — IBS, colitis); (2) metabolism and growth (fat loss, muscle growth, more); (3) longevity (staving off tumor growth, potentially lifespan — very experimental); (4) vitality (mood and libido, both sexes).

[15:41] Peptides for rejuvenation and repair. Injuries are part of athletic life. Beyond rest and physical therapy (and the cold-vs-heat debate, with growing emphasis on heat for blood flow), people ask: can I take something to accelerate healing? The most-explored is BPC — body protection compound 157, a synthetic peptide resembling one that occurs naturally in the gut.

[17:36] Why a gut peptide for wound healing? The gut lining turns over cells frequently — and tissue turnover is essentially the same process as wound healing/repair (like skin: scab, then new cells mend underneath). So a gut peptide involved in tissue turnover doubling as a repair compound isn’t surprising. Tissue rejuvenation/repair almost always involves angiogenesis — new vascular supply (capillaries/vessels), meaning new endothelial cells.

[19:45] A clear effect of BPC-157: it encourages cellular turnover, cellular migration, and new blood supply via angiogenesis. Injure your elbow (nerves, ligament, tendon, muscle all affected) and — in animal studies (where the vast majority of BPC-157 data come from) — BPC-157 increases blood flow via angiogenesis. It somehow recognises injured vessels/capillaries and promotes the enzyme eNOS (endothelial nitric oxide synthase), forming more vasculature at and around the injury, delivering blood plus growth factors that rejuvenate tissue. It also encourages fibroblast migration and growth — fibroblasts provide firm substrate bridging injuries (helping torn tendons/ligaments restore).

[22:15] There’s a long history of using gastric juices/the stomach environment to preserve and rejuvenate tissue (e.g. historically, severed fingers/hands placed in the gut to keep tissue viable before grafting). Physicians suspected something in gastric juices was beneficial — one compound turned out to be BPC (synthesized as BPC-157).

[23:46] How does a gut peptide reach an injured elbow or Achilles? Still somewhat a mystery. BPC-157 can exit the gut, but its trafficking to injury sites isn’t clear. The community debates systemic vs local injection; there’s no formal science. There’s a sizeable peer-reviewed literature (rats/mice, since ~1993) but, to my knowledge, only one human study — not a clinical trial, and frankly poorly performed (self-report). So hundreds of thousands, perhaps millions, now take BPC-157 with essentially no human data.

[26:07] It’s an unusual mix: rich, even quality animal literature, a dearth of rigorous human study, and a very rich set of anecdote. Typical route: SubQ or IM, a few inches off the belly button (systemic), or local to the injury. We can’t rule out placebo (placebo effects are very real). But given the overwhelming anecdote and widespread use, I’d be remiss not to cover it. The anecdote suggests delivery mode (systemic vs local) doesn’t matter much, though some claim local works better.

[27:56] Two things about BPC-157: (1) injury seems important — injury appears to signal BPC-157 to create vasculature/fibroblast growth at the site; there’s no evidence it systemically increases vascular growth (though it might — hence tumor cautions). (2) Safety: very high LD50 — as high as 2 g/kg. This does not mean take high doses. Typical therapeutic dose: 300–500 mcg SubQ, 2–3×/week, often an 8-week course, then 8–10 weeks off. Some take it daily/indefinitely — I think that’s a bad idea. I’m not suggesting anyone take BPC-157; this is to inform your decision and stress sourcing.

[30:25] Reason to avoid: BPC-157 has a small but meaningful effect upregulating growth-hormone receptors. Good for healing at an injury site, but for someone with a tumor, more GH receptors around the tumor could grow it. Tumors thrive on blood flow/growth factors, so BPC-157 could maintain or accelerate a tumor that might otherwise stay small — a tumor-growth risk. One mechanism: BPC-157 upregulates VEGF (vascular endothelial growth factor). The cancer drug Avastin is a VEGF inhibitor; BPC-157 does the opposite. So if concerned about cancer/tumors, BPC-157 is probably not for you.

[32:55] Why do so many take it? The anecdote is strong (rapid shoulder recovery, even claims of recovery from tissue transections), and animal data are impressive (sciatic nerve, Achilles regrowth — some with complete transection). On average tissues seem to repair faster with systemic BPC-157. But the tumor concerns and lack of human data are real. Take the minimal effective dose, don’t dose daily/continuously, and monitor health metrics for anything resembling tumor growth.

[35:16] [sponsor segment omitted — AG1]

[36:40] Another repair peptide: thymosin beta-4 and its truncated version TB-500. Thymosin beta-4 is produced naturally by the thymus, present in children and shrinking with age — children recover faster and heal with less scarring, which inspired synthesizing thymosin beta-4 / TB-500. Again, vast animal data show increased rate/thoroughness of wound healing. Mechanistically, vs BPC-157, thymosin beta-4 promotes growth/infiltration of many cell types for repair — stem-cell proliferation, extracellular-matrix growth (rigidity/stability around cells). Many people note TB-500 as “growth-promoting” — as far as I know it isn’t; it doesn’t act on the GH pathway, it’s for tissue repair. Often combined with BPC-157.

[40:46] Peptides for metabolism and growth — necessarily a discussion of growth hormone (GH). GH is secreted by the pituitary (near the roof of the mouth, off the brain stalk), which gets input from the hypothalamus (neurons that tell it to release or suppress GH). Early in life we secrete tons of GH, especially in early sleep — why babies/kids/teens sleep so much and grow during sleep. After ~age 30, nightly and daytime GH falls ~15% per decade, reducing metabolism, fat loss, muscle growth, mood/well-being, and vitality. GH potently increases ATP production (energy/metabolism).

[43:04] IGF-1 (insulin-like growth factor 1), made by the liver in response to GH, does many GH-like things plus blood-sugar regulation. Cascade: hypothalamus releases growth-hormone-releasing hormone → anterior pituitary releases GH → GH circulates (ATP, repair, tissue growth, full stature) → reaches liver → IGF-1 release (synergistic + some distinct effects). You can buy synthetic GH (injected SubQ at night) but GH grows tissues indiscriminately (including tumors) and is subject to negative feedback that shuts down endogenous production.

[45:12] Hence peptides that stimulate GH (and downstream IGF-1) without directly hitting the GH pathway — they mimic what the hypothalamus releases onto the pituitary. These are secretagogues. Two categories: GHRH peptides (growth-hormone-releasing-hormone) and growth-hormone-releasing peptides — confusing names, so I’ll relabel them type 1 and type 2.

[46:58] Type 1 are best-tested in humans, several FDA-approved, prescribed off-label. Sermorelin — synthetic GHRH mimic, FDA-approved for short stature, by prescription/compounding pharmacy; raises circulating GH and IGF-1. Typical dose 200–400 mcg, at night before sleep, 3–5×/week (continuous 7-day use can cause mild desensitization). People like the vitality, muscle growth, fat loss, and deeper sleep. I’ve taken sermorelin on/off for a couple of years (1–2 nights/week) and largely stopped: it made early-night sleep very deep but cut my REM (per Eight Sleep/Whoop) — it seemed to trade REM for deep sleep. The deep-sleep increase is well documented.

[49:44] Tesamorelin (brand Egrifta) — FDA-approved type-1 peptide for reducing visceral adiposity in HIV patients (visceral fat is metabolically problematic). Similar effects to sermorelin; differs by small amino-acid sequence changes; longer-lasting → ~3×/week.

[50:40] CJC-1295 — a variant with an added DAC (drug-affinity complex) making it very long-lasting → 1–2×/week. But CJC-1295 entered clinical trials and there was a death related to cardiovascular dysfunction; it’s known to cause fluid retention/increased fluid volume (possibly related). Speculative, but given sermorelin/tesamorelin alternatives, I don’t know why one would specifically choose CJC-1295 until safety issues resolve.

[52:35] [sponsor segment omitted — Element]

[53:56] Type 2 peptides encourage GH release by mimicking/stimulating ghrelin (the hunger peptide, which also raises anxiety somewhat). Ghrelin potently drives the GH pathway → robust GH increases, but with hunger/anxiety. Ipamorelin (don’t confuse with tesamorelin) is type 2: raises ghrelin (hunger), increases GH directly and by suppressing somatostatin (GH’s brake) → lots of GH; also improves deep sleep (unknown REM cost). Hexarelin — by prescription, the strongest GH stimulator (pulses 2–3× greater) — but raises prolactin (suppressed libido, fluid retention, malaise) and, most problematically, can desensitize GHRH receptors, potentially shutting down response to hexarelin, other peptides, and even your own endogenous GHRH. Work with a physician; avoid high doses.

[56:58] Other type-2: GHRP-2, GHRP-3, GHRP-6 — different sequences, same goal (more GH); GHRP-3 potently raises GH but also prolactin and cortisol (>doubling), which matters by time of day (cortisol should be high AM, low PM/night). Note: GH peptides (type 1 or 2) are taken ~20–30 min before sleep, at least 1.5 hours after food and no food for 30+ min after — food/elevated blood sugar blunts the GH/IGF-1 response. MK-677 is an oral (non-injectable) GHRP with the same issues (cortisol, sometimes prolactin).

[58:49] Zooming out: synthetic peptides can potently raise GH and IGF-1. Work with a board-certified physician; get clean compounds. Type 1: sermorelin, tesamorelin (FDA-approved, off-label use; 3–5×/week; tesamorelin longer-lasting), CJC-1295 (possible unresolved safety). Type 2: hexarelin (potent but desensitization risk), ipamorelin (direct + somatostatin suppression), GHRP-2/3/6 and MK-677 (potent but raise cortisol, some desensitization).

[01:00:38] Two more points. (1) Vendors/physicians often combine GH peptides (e.g. sermorelin/tesamorelin + hexarelin, or ipamorelin + CJC-1295). Not inherently bad — the logic is to hit different modes of action — but get the relative dosing right to avoid unnecessary prolactin/cortisol and redundant pathway hits; work with someone experienced. (2) Risks of augmenting GH: with GH itself, carpal tunnel, cartilage growth, head/face/body structural changes, “lean but distended gut,” brow-bone thickening, altered skin texture. Peptides change body structure less dramatically than GH itself — but any GH augmentation raises tumor/cancer risk (GH and IGF-1 grow tissues indiscriminately). Combining a GH peptide with BPC-157 could increase both size and vascularization of a tumor.

[01:04:42] Why take this at all? People like elevated-GH effects and faster recovery — but always a benefit/risk trade-off. Sermorelin and tesamorelin are FDA-approved (not for all the purposes people use them). Considerations: age (under 30, little reason to augment GH absent clinical need; you already make a lot); over 30, ensure no tumors/cancers, use the minimal effective dose and the mildest compound to avoid receptor desensitization. I tried sermorelin briefly; the REM reduction was enough that I mostly stopped.

[01:06:14] Peptides for longevity. Besides thymosin beta-4 (a youth/repair agent, not longevity per se), the big one is epitalon (also spelled epithalon). Like BPC-157, there are many animal studies. Epithalon mimics epithalamin, a peptide secreted by the pineal gland (whose pinealocytes also secrete melatonin at night; melatonin is suppressed by light via an eye→brain pathway through the cervical ganglion to the pineal). Epithalamin is released especially early in life, with anti-inflammatory effects, and appears able to adjust telomere length (the telomere↔longevity link is controversial — excitement, then doubt, now back-and-forth).

[01:08:35] Epithalon (synthetic, clean from compounding pharmacies) is used as a longevity agent based largely on animal data: tumor-growth suppression, telomere lengthening, and recalibration of circadian/melatonin disruptions of aging. As we age, melatonin and epithalamin decline, and tissue-inflammation markers rise. There are theories about pineal regression with age (some niche/false, e.g. fluoride; some gaining data). The logic mirrors the thymus argument: a youthful pineal secretes epithalamin → deep sleep, robust repair, long cellular life; supplementing epithalamin aims to mimic that. But it’s a leap — no clinical trials show that X amount of epithalamin extends human life.

[01:12:05] Peptides for vitality — mood and libido. Main players: melanocyte-stimulating-hormone (MSH)-related peptides. The pituitary’s medial segment releases MSH, which stimulates skin melanocytes (pigmentation). The synthetic melanotan 1, 2, 3, 4, 5 mimic MSH but act preferentially on different MSH receptors. The melanocortin system: UV-B light to eyes/skin → hypothalamus → pituitary → MSH → melanocytes → tanning; in parallel, light stimulates dopamine release (why sunshine lifts mood/energy/motivation/libido). Well conserved across species (animals darken and breed in spring/summer).

[01:14:57] Melanotan 1 does not cross the blood-brain barrier (tans skin only). Melanotan 2/3/4/5 cross the BBB → effects on mood, libido (↑), and appetite (↓), plus tanning. PT-141 (drug name Vyleesi) activates the melanocortin system and is FDA-approved for premenopausal hypoactive sexual desire (women); men take it off-label. It also stimulates pigmentation. Side effects: nausea (gut MSH receptors), skin flushing, raised blood pressure; melanoma caution.

[01:17:05] Kisspeptin — discovered relatively recently; made in the brain, upstream of hypothalamic signals driving the pituitary for reproduction. Cascade: kisspeptin → GnRH → LH/FSH → testosterone/estrogen (LH drives gonadal testosterone/estrogen; FSH drives follicle/sperm). Kisspeptin activates puberty and downstream vitality/libido. Synthetic kisspeptin is prescribed for hypothalamic amenorrhea (absent periods from a hypothalamic deficit). Kisspeptin antagonists treat menopausal vasomotor symptoms (night sweats). Some take kisspeptin peptides for vitality/libido — a wild card, given recent discovery and pleiotropy.

[01:21:55] Every peptide we examine — ghrelin, orexin/hypocretin, GLP-1 — shows pleiotropic effects; rarely one specific action. The peptide landscape is enormous (likely hundreds of thousands), with overlapping/synergistic effects we’re just beginning to appreciate. I understand the excitement for repair, aesthetics, mood — but people wrongly assume peptides are “safe/innocuous” because they aren’t hormone therapies. They are very potent, with many effects; we’re in early days. Work with a good board-certified physician, ensure clean sourcing, do regular blood testing, and monitor for tumor growth. Peptide therapeutics are exciting for disease treatment and augmentation of mental/physical health — a landscape we’ll keep exploring.

[01:24:06] [closing — YouTube/Spotify/Apple, Momentous, social, newsletter outro omitted]